马耳他 - 英文 - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - varicella virus, oka strain, live, attenuated, measles virus, schwarz strain, mumps virus, jeryl lynn, level b, rubella virus, wistar ra - powder and solvent for solution for injection in pre-filled syringe - varicella virus oka strain (live, attenuated) measles virus - schwarz strain mumps virus jeryl lynn (level b) strain (live, attenuated) rubella virus wistar ra 27/3 strain (live, attenuated) - vaccines

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

bio products laboratory ltd - varicella-zoster immunoglobulin human - solution for injection - 250mg

加拿大 - 英文 - Health Canada

massachusetts public health biologic laboratories - varicella zoster immunoglobulin (human) - liquid - 125unit - varicella zoster immunoglobulin (human) 125unit - serums

加拿大 - 英文 - Health Canada

massachusetts public health biologic laboratories - varicella zoster immunoglobulin (human) - liquid - 100unit - varicella zoster immunoglobulin (human) 100unit - serums

马耳他 - 英文 - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - varicella virus, oka strain, live, attenuated, measles virus, schwarz strain, mumps virus, jeryl lynn, level b, rubella virus, wistar ra - powder and solvent for solution for injection - mumps virus jeryl lynn (level b) strain (live, attenuated) rubella virus - wistar ra27/3 strain varicella virus oka strain (live, attenuated) measles virus - schwarz strain - vaccines

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg; leucine, quantity: 0.432 mg - injection, powder for - excipient ingredients: lactose; sorbitol; mannitol; threonine; serine; proline; glycine; alanine; valine; methionine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg - injection, powder for - excipient ingredients: lactose; mannitol; sorbitol; threonine; serine; proline; glycine; alanine; valine; methionine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml - injection, powder for - excipient ingredients: lactose; mannitol; sorbitol; threonine; serine; proline; glycine; alanine; valine; methionine; isoleucine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immuncompromised patients with no history of the disease.

美国 - 英文 - NLM (National Library of Medicine)

merck sharp & dohme llc - varicella-zoster virus strain oka/merck live antigen (unii: gpv39zgd8c) (varicella-zoster virus strain oka/merck live antigen - unii:gpv39zgd8c) - varicella-zoster virus strain oka/merck live antigen 1350 [pfu] in 0.5 ml - varivax is a vaccine indicated for active immunization for the prevention of varicella in individuals 12 months of age and older. do not administer varivax to individuals with a history of anaphylactic or severe allergic reaction to any component of the vaccine (including neomycin and gelatin) or to a previous dose of a varicella-containing vaccine. do not administer varivax to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. disseminated varicella disease and extensive vaccine-associated rash have been reported in individuals who are immunosuppressed or immunodeficient who were inadvertently vaccinated with a varicella-containing vaccine. do not administer varivax to individuals with an active febrile illness with fever >101.3°f (>38.5°c). do not administer varivax to individuals with active, untreated tuberculosis (tb). do not administer varivax to individuals who are pregnant or planning on becoming pregnant in the next 3 months. wild-type varicella is known to cau

美国 - 英文 - NLM (National Library of Medicine)

aptevo biotherapeutics llc - human varicella-zoster immune globulin (unii: 33t61iwl27) (human varicella-zoster immune globulin - unii:33t61iwl27) - human varicella-zoster immune globulin 125 [iu] - varizig® [varicella zoster immune globulin (human)] is indicated for post-exposure prophylaxis of varicella in high risk individuals. high risk groups include: - immunocompromised children and adults, - newborns of mothers with varicella shortly before or after delivery, - premature infants, - neonates and infants less than one year of age, - adults without evidence of immunity, - pregnant women. varizig administration is intended to reduce the severity of varicella. administer varizig as soon as possible following varicella zoster virus (vzv) exposure, ideally within 96 hours for greatest effectiveness. - there is no convincing evidence that varizig reduces the incidence of chickenpox infection after exposure to vzv. - there is no convincing evidence that established infections with vzv can be modified by varizig administration. - there is no indication for the prophylactic use of varizig in immunodeficient children or adults when there is a past history of varicella, unless the patient is undergoing bone m